Clinical Trial

A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study will evaluate the safety, tolerability, and immunogenicity (your immune system's reaction) of 3 dose levels of the study vaccine called Herpes Zoster IN001 mRNA Vaccine (IN001) in healthy participants who are between 50 and 79 years of age.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-26.
Trial Details
NCT Number NCT07205796
Lead Sponsor Shenzhen Shenxin Biotechnology Co., Ltd
Conditions Herpes Zoster
Enrollment 480 participants
Start Date 2026-05-01
Primary Completion 2027-12-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-10-07